GM-CSF
Granulocyte macrophage colony-stimulating factor (particularly corticosteroid-resistant asthma). [1] [2] [3] Patients with COPD and asthma are commonly prescribed long-term inhaled beta-2 agonists and corticosteroids. The detailed effects of these treatments on neutrophil phagocytic function are relatively poorly understood, though it has been suggested that beta-2 agonists can impair neutrophil function. 4 It is also increasingly recognized that acquired neutrophil dysfunction is common in critically ill patients, 5 and is independently associated with a significantly increased risk of subsequent hospital-acquired infection (HAI). 6 Impaired neutrophil function can be restored to normal, ex vivo, through administration of granulocyte-macrophage colony-stimulating factor (GM-CSF). 6 This suggests the potential to develop pharmacological strategies to restore specific defects in neutrophil function for clinical benefit. The potential importance of developing non-antibiotic-based pharmacological prevention strategies is enormous. For example, at a conservative estimate there are 1.7 million HAIs in the US annually, 7 at a time when antibiotic resistance is a global concern and few new antibiotics are in development.
The aims of this study were therefore to characterize the effects of beta-2 agonists, corticosteroids and critical illness on neutrophil function, and to identify novel ways of modulating pathways involved in the impairment of neutrophil phagocytosis, in the hope of identifying candidates with the potential to restore efficient phagocytosis.
METHODS

Reagents
Salbutamol, salmeterol, isoprenaline, fluticasone, beclomethasone, budesonide, SQ 22536, ICI 118,551, atenolol, prostaglandin E1 (PGE1), Y27632, zymosan derived from
Saccharomyces cerevisiae and Giemsa staining solution were from Sigma Aldrich (Gillingham, UK). KT5720, mouse anti-human GM-CSF receptor antibody (IgG2a), and murine IgG2a negative control antibody were from Merck (Darmstadt, Germany). St-Ht31
and St-Ht31 control peptide were from Promega (Madison, USA). Antibodies against RhoA and protein kinase A (PKA) were from Cell Signaling (Hitchin, UK). Dextran was from Pharmacosmos (Holbaek, Denmark). Percoll Plus was from GE Healthcare (Little Chalfont, UK). Iscove's Modified Dulbecco's Medium (IMDM) was from Life Technologies (Paisley, UK). 8CPT-2Me-cAMP, N 6 -benzoyladenosine-cAMP (6-Bnz-cAMP) and GGTi 298 were from Tocris Bioscience (Bristol, UK). PKA inhibitor IV was from Santa Cruz Biotechnology (Dallas, TX, USA), ESI-09 was from Biolog (Bremen, Germany). Rho G-lisa was from Cytoskeleton (Denver, USA). PKA activity assay was from Abcam (Cambridge, UK).
Ethical approvals
Ethical approval to obtain neutrophils from healthy volunteers was granted by the County 
Isolation of peripheral blood neutrophils
Neutrophils were isolated from whole blood by dextran sedimentation and fractionation over discontinuous Percoll gradients as previously described. 8 Only samples yielding ≥ 95% neutrophil purity (assessed by morphological analysis) and ≥ 95% viability (assessed by trypan blue exclusion) were used.
Phagocytosis assay
Phagocytosis of serum-opsonized zymosan by neutrophils was assessed as previously described. 5 A variety of reagents were incorporated into the phagocytosis assay, individually or in combination, to determine the effect on phagocytosis. Doses for each condition are described in figure legends or in the Results section. All incubations described were performed at 37°C in 5% CO 2 . Unless otherwise stated, neutrophils were prepared in IMDM containing 1% autologous serum, and were adherent to tissue culture plastic. In all experiments in which salbutamol, salmeterol, corticosteroids or PGE1 were used to impair neutrophil phagocytosis, the application was for 30 minutes, prior to the addition of serumopsonized zymosan for a further 30 minutes. Phagocytosis was quantified in terms of the proportion of neutrophils containing 2 or more zymosan particles at light microscopy.
Bacterial Killing Assay
The ability of neutrophils to kill live bacteria was assessed using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)-based colorimetric assay as previously 
RhoA and PKA activity assays
RhoA and PKA activity were measured using an enzyme-linked immunosorbent assay (ELISA; Rho G-lisa) as per the manufacturer's instructions. Neutrophils were adhered to tissue culture plates before being exposed to serum-opsonized zymosan or vehicle control for 5 minutes. Cells were washed in ice-cold phosphate-buffered saline (PBS) and then lysed.
Aliquots were taken for estimation of total protein with the remainder snap frozen in liquid nitrogen and stored at -80°C. Samples were equalized for total protein concentration and analyzed using a BMG FluoStar Optima plate reader. Samples were assessed for total RhoA and total PKA by boiling in Laemmli sample buffer before Western blot analysis using antiRhoA or anti-PKA antibodies.
Statistical Analysis
The Statistical Package for the Social Sciences17.0 (IBM, USA) was used. In the figures shown, unless otherwise stated, results are derived from 6 independent experiments (ie conditions performed using neutrophils from 6 different donors). Statistical comparisons were by one-way ANOVA with Bonferroni's post-hoc correction, and data expressed as mean (bar) and standard error of the mean (error bars). P values <0.05 were considered statistically significant, and in the figures * = p<0.05, ** = p<0.01, *** = p<0.001.
RESULTS
With the exception of results shown in Figure 7 C and D, all data relate to neutrophils derived from healthy volunteers.
Incubation of neutrophils from healthy volunteers with the short-acting beta-2 agonist salbutamol resulted in a dose-dependent impairment of phagocytosis ( Figure 1A ). The longacting beta-2 agonist salmeterol induced a similar effect ( Figure 1A ). Neither salbutamol nor salmeterol influenced neutrophil viability at the concentrations used (data not shown). The selective beta-2 antagonist ICI 118,551 prevented the anti-phagocytic effects of salbutamol and salmeterol, without inhibiting the impairment of phagocytosis induced by the beta-1 agonist isoprenaline. In contrast, atenolol (a predominantly beta-1 antagonist with partial beta-2 antagonist activity) prevented the anti-phagocytic effect of isoprenaline, but not the effects of salbutamol or salmeterol ( Figure 1B ). The inhibitory effects of salbutamol on neutrophil phagocytosis were also reduced, in a dose-dependent manner, by the adenylate cyclase inhibitor SQ22536, ( Figure 1C ). Salbutamol at 10µM was used to induce reproducible phagocytic impairment in later experiments, unless otherwise stated.
Incubation of neutrophils with the glucocorticoids beclomethasone, fluticasone and budesonide resulted in a dose-dependent impairment of neutrophil phagocytosis ( Figure 2A ).
The combination of beclomethasone and salbutamol produced an effect similar to salbutamol alone ( Figure 2B ).
The results in Figure 1 suggested that beta-2 agonist-induced impairment of neutrophil phagocytosis is mediated via cyclic adenosine monophosphate (cAMP), and that mechanisms downstream of cAMP signaling may provide novel opportunities for pharmacologic restoration of neutrophil phagocytosis. PGE1 was selected as a separate stimulus known to increase intracellular cAMP. PGE1 was incubated with neutrophils, and produced a similar impairment of phagocytosis ( Figure 3A ). PKA is a key target for intracellular cAMP, and is located at strategic compartmentalized locations within cells through interaction with A kinase anchoring proteins (AKAPs). 10 Pre-incubation of neutrophils with St-Ht31 (a cellpermeable inhibitor of AKAPs) prevented impairment of neutrophil phagocytosis mediated by salbutamol ( Figure 3B ). This suggested that cAMP impairs neutrophil phagocytosis predominantly via activation of PKA. To test this further, salbutamol-treated neutrophils were pre-incubated with two separate PKA inhibitors, KT5720 and PKA inhibitor IV. Both inhibitors prevented salbutamol-induced impairment of phagocytosis. ( Figure 3C ). We further demonstrated that a PKA-specific cAMP analogue, 6-Bnz-cAMP, significantly reduced neutrophil phagocytosis ( Figure 3D ).
In parallel with the studies of phagocytosis described, we confirmed that salbutamol increases PKA activity in neutrophils and that this effect can be blocked by a PKA inhibitor ( Figure   4A ). RhoA is inherently involved in cytoskeletal organization in the neutrophil, 11 and adequate function of RhoA is pivotal to effective phagocytosis. To investigate the downstream mechanisms of salbutamol-induced impairment of phagocytosis further, we therefore studied the effect of salbutamol on RhoA activity. Salbutamol significantly reduced
RhoA activity in neutrophils exposed to zymosan, without affecting the total amount of RhoA proteins ( Figure 4B ). This effect could be significantly abrogated by PKA inhibition ( Figure   4B ). These findings suggested that salbutamol stimulates PKA, which inhibits RhoA activity, which in turn impairs phagocytosis of zymosan.
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The data presented in Figures 3 and 4 , in addition to our previous data, 6 suggested that RhoA plays a part in regulating efficient phagocytosis. The next question was whether phagocytosis could be restored through other intracellular pathways, when RhoA activity was blocked. The role of PKA both in mediating beta-2-induced impairment of phagocytosis and in reducing
RhoA activity was interesting in this regard, as cAMP can exert divergent functions in cells, depending on whether it engages PKA or alternative effectors. One such alternative effector is EPAC (exchange protein directly activated by cAMP), which is typically associated with Rap-1 signaling. [12] [13] [14] We therefore used an analog of cAMP that selectively activates EPAC (8CPT-2Me-cAMP) to determine the effect of routing cAMP away from the RhoA pathway.
8CPT-2Me-cAMP reversed salbutamol-induced impairment of phagocytosis ( Figure 5A , "salbutamol" columns). The protective effect was removed by an EPAC-specific inhibitor, ESI-09 ( Figure 5A , "salbutamol" columns). GM-CSF, which can reverse impaired neutrophil phagocyosis induced by C5a or by critical illness, 6 also reversed salbutamol-mediated phagocytic impairment ( Figure 5A , "salbutamol" columns). However ESI-09 could not prevent the protective effect of GM-CSF, implying that GM-CSF does not act through EPAC ( Figure 5A , "salbutamol" columns). All of these results could be replicated when PGE1was substituted for salbutamol ( Figure 5A , "PGE1" columns).
To test the role of RhoA in restoration of phagocytosis by GM-CSF and 8CPT-2Me-cAMP, the Rho kinase inhibitor Y27632 was also used to drive impairment of neutrophil phagocytosis. Under these circumstances 8CPT-2Me-cAMP, but not GM-CSF, was capable of restoring neutrophil phagocytosis ( Figure 5A , "Y27632" columns). This indicated that GM-CSF exerts its restorative effect through RhoA, while 8CPT-2Me-cAMP does not.
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We therefore went on to study the effects of EPAC activation on RhoA activity. Interestingly, application of 8CPT-2Me-cAMP to healthy neutrophils reduced RhoA activity by 63%
( Figure 5B , left panel). Furthermore, 8CPT-2Me-cAMP had no effect on salbutamol-induced impairment of Rho activity ( Figure 5B , right panel). Both these results contrasted with the effects of GM-CSF ( Figure 5B ), which were more like those for PKA inhibition ( Figure 4B ).
This suggested that 8CPT-2Me-cAMP does not exert its protective effects on phagocytosis through RhoA. As EPACs can act as guanine-exchange proteins for the Rap family, 13 we tested whether a Rap inhibitor (GGTi 298) could interfere with the protective effects of 8CPT-2Me-cAMP. GGTi 298 significantly abrogated the protective effects of 8CPT-2Me-cAMP on phagocytosis ( Figure 5C ). To confirm that 8CPT-2Me-cAMP exerted none of its effects through the GM-CSF receptor, we incubated neutrophils with an antibody that blocks the GM-CSF receptor. The blocking antibody prevented the phagocytosis-protective effects of GM-CSF, but not those of 8CPT-2Me-cAMP ( Figure 5D ). The effect of glucocorticoids on phagocytosis could also be partly restored by 8CPT-2Me-cAMP ( Figure 5E ). Figure 5 indicates an effect of 8CPT-2Me-cAMP on phagocytosis of inert particles. In order to test a more relevant physiological response, the effect on bacterial killing was assessed.
8CPT-2Me-cAMP significantly restored the capacity of neutrophils to kill laboratory and clinical strains of the Gram positive pathogen S. aureus ( Figure 6A and B) and the Gram negative pathogen P. aeruginosa ( Figure 6C and D) .
Collectively, the results above suggested that neutrophil phagocytosis can be impaired through a PKA-dependent pathway. They further suggested that selective EPAC activation can bypass this pathway, thereby representing a potentially novel means to restore neutrophil phagocytosis. They also suggested that the protective effects exerted by 8CPT-2Me-cAMP 14 and GM-CSF are independent of one another. We therefore sought to test the potential clinical relevance of these findings in two scenarios.
Firstly, plasma from patients in the BALTI-2 trial (a randomized controlled trial of intravenous salbutamol versus placebo in critically ill patients), 15 was applied to healthy neutrophils. On six separate occasions plasma from patients (n=13 who received placebo, n=5 who received salbutamol) was applied in a blinded fashion to neutrophils isolated from healthy volunteers (ie six separate healthy volunteers provided neutrophils, the plasma applied was the same each time). Plasma from salbutamol-treated and placebo-treated patients impaired neutrophil phagocytosis to a similar degree ( Figure 7A ). Given the striking degree of phagocytic impairment induced by plasma from critically ill patients, these experiments were repeated to determine whether 8CPT-Me-cAMP could reverse this effect. Both 8CPT-2Me-cAMP and GM-CSF reversed the anti-phagocytic effect of the plasma ( Figure 7B ). due to missing data in 1 patient), and PaO 2 :FiO 2 ratio 173 mmHg (SD 78, n=15 due to missing data in 1 patient). The principal diagnoses were pneumonia (n=7), urinary sepsis (n=3), infective endocarditis, biliary sepsis, pancreatitis, multiple trauma, acute colitis, and post-operative peritonitis (all n=1). Both treatments resulted in significant improvement in phagocytic capacity ( Figures 7C and 7D) .
A schematic summary of our main findings is shown in Figure 8 .
DISCUSSION
The findings presented here may have potential clinical implications for critically ill patients at the highest risk of developing hospital-acquired infection, 6 where EPAC activation and/or selective signaling through Rap-1 emerge as interesting areas for possible therapeutic exploration. The capacity to restore efficient killing of Gram positive and Gram negative pathogens commonly implicated in HAI is encouraging in this regard. While EPAC activators have not been used clinically to date, they have shown promise in, for example, in vivo models of macular degeneration. 16 Our overall findings extend data showing that the generation of cAMP impairs neutrophil phagocytosis. In our hands, the beta-2 agonist effect could be abolished by selective inhibitors of PKA, suggesting that cAMP selectively targets PKA in neutrophils. In several cell types, cAMP is directed to PKA through the activity of AKAPs. 17, 18 This process appears to be replicated in neutrophils, which are known to contain AKAPs, 19 and in our experiments an AKAP inhibitor was also capable of partially restoring phagocytosis in beta-2 agonist-treated neutrophils.
The anti-phagocytic activity of beta-2 agonists appeared to be mediated, at least in part, by inhibition of RhoA. Similar findings have been described for impaired phagocytosis induced by excessive C5a. 5 This suggests a similar downstream mechanism for impairment of neutrophil phagocytosis mediated through the beta-2 receptor, PGE1 receptor, and CD88 (the receptor for C5a). The implication is that RhoA inhibition is a central downstream process in mediating the phagocytic impairment induced by engaging these receptors. A similarly important role for RhoA in regulating complement-mediated phagocytosis has been described in murine macrophages. 20 A key finding of our study was that, in striking contrast to GM-CSF, EPAC activation not only failed to restore salbutamol-driven impairment of RhoA activation, but knocked down constitutive RhoA. Despite this, both GM-CSF and the EPAC activator could completely reverse beta-2 agonist-and PGE1-induced impairment of neutrophil phagocytosis. This formed the basis for the observation that EPAC and GM-CSF have alternative modes of action. In keeping with this, Rho kinase inhibition prevented phagocytic restoration caused by GM-CSF, but had no effect on the restorative effects of EPAC activation ( Figure 5A ). Taken together these findings suggested that GM-CSF and EPAC activation, while both capable of restoring phagocytosis, had opposing effects on RhoA. EPAC is known to signal through Rap-1 in other cell types, 21, 22 raising the possibility that EPAC may selectively signal through Rap-1, bypassing RhoA. The confirmation of two independent pathways for restoration of neutrophil phagocytosis is novel, to our knowledge, though interestingly a similar situation has been described in a murine macrophage cell line. 23 Certain cautions are required when considering our data. For example, our ex vivo conditions may be insufficiently representative of those in situ. Our experiments were performed in blood neutrophils adhered to tissue culture plastic, and it is unlikely that phagocytic capacity (and response to molecules such as EPAC analogues or GM-CSF) would be replicated identically in neutrophils within body tissues. Any implications around the significance of our findings in tissue neutrophils therefore remain necessarily speculative. In addition, our routinely used concentration of salbutamol,10 µM, is higher than that often described in clinical scenarios. The original BALTI trial generated estimated salbutamol concentrations in the low micromolar range. 24 Our rationale for studying plasma from patients in the BALTI-2 trial related to the use of intravenous beta-2 agonists. In hindsight, while salbutamol concentrations were not specifically measured in the BALTI-2 study, we were always unlikely to observe any effect of salbutamol over and above the profound anti-phagocytic effect of plasma from critically ill patients.
In addition, we focused on neutrophil phagocytosis. The concentrations of salbutamol used have been shown to reduce neutrophil chemotaxis in other studies. 25 We concentrated on phagocytosis because impaired ex vivo phagocytosis of serum-opsonized zymosan predicts nosocomial infection in a clinical setting. 6 We should emphasize that in our bacterial killing experiments ( Figure 6 ) in particular we cannot infer that the effectiveness of GM-CSF or 8-CPT-2Me-cAMP is attributable to effects on phagocytosis alone, as effects on many other innate immune functions of neutrophils could be contributing.
Furthermore, interpretation of studies of this nature may be constrained by lack of absolute specificity of inhibitors. For example molecules such as KT5720 can influence targets other than PKA, and Y27632 certainly does not inhibit all RhoA functions. Finally, in advocating the further study of EPAC analogs or Rap-1 activators as potential therapeutics, we must obviously remain alert to the fact that EPAC and Rap-1 are involved in multiple homeostatic processes, and future work will be required to take due consideration of potential toxicities.
In summary, EPAC activation represents a novel potential therapeutic avenue for the restoration of neutrophil phagocytosis, and deserves further investigation.
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Acknowledgements. We are extremely grateful to all of the volunteers and patients who provided blood and to members of staff in all of the participating intensive care units. The picture represents a neutrophil, divided into 3 illustrative sections. Section 1 is a schematic of normal phagocytosis. Upon engagement of the appropriate phagocytic receptor, opsonized zymosan is thought to signal through RhoA, which plays a part in coordinating polymerization of filamentous actin (F-actin), allowing the efficient organization of the phagosome, with subsequent phagocytosis. Section 2 illustrates the proposed disruption of this system by beta-2 agonists or PGE1. These stimuli generate cAMP, which appears to preferentially activate PKA, through interaction with AKAP. Activation of PKA inhibits RhoA activation, preventing efficient phagocytosis. Other anti-phagocytic stimuli, such as an excess of C5a, also appear to exert their effects through inhibition of RhoA. 6 Section 3 demonstrates the proposed restorative role for EPAC activation. We propose that cAMP 28 preferentially activates PKA in neutrophils in response to stimuli that impair phagocytosis.
Directing cAMP through EPAC results in signaling through Rap-1, which allows efficient phagocytosis to proceed, even when RhoA is simultaneously blocked. On the left of the diagram, GM-CSF is seen engaging with its receptor on the neutrophil. GM-CSF can replenish RhoA activity, but if Rho kinase is blocked the effects of GM-CSF are abrogated. In contrast, even when Rho kinase is blocked, EPAC activation can still rescue phagocytosis, suggesting that EPAC activation and GM-CSF restore phagocytosis through independent mechanisms.
